Qiagen

Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform. While DNA can reveal biological insights, proteins provide the actual insights into the functions of our bodies. The company is in the process of developing a pioneering, next-generation protein sequencing platform that will empower researchers to acquire unprecedented insights into both biology and diseases.

Actome focuses on developing emulsion coupling technology for life science research and personalized medicine.

ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Drug Response Dx is based in Hennigsdorf, Germany and was founded in February 2012 by Dr. Zoltán Konthur, Dr. Jörg-M.  Hollidt, Dr. Karl Skriner and Dr. Joachim Rautter. The biomarker set is prevalidated; the biochemicals and test samples  are present. The proof of concept in serums from RA patients is established.

Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples. We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

QIAGEN provides technologies and products for preanalytical sample preparation and linked molecular assay solutions. QIAGEN also supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics.QIAGEN offers its sample and assay consumable products in kit form.

<div>  <p>    QIAGEN provides technologies and products for preanalytical sample preparation and linked molecular assay solutions. QIAGEN also supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics.QIAGEN offers its sample and assay consumable products in kit form.  </p></div>

Leveraging personal data for custom-fit diagnosis and treatment

Qiagen

Featured Industries

Recent Updates

QIAGEN partners with Servier to develop new test for AML

Neuron23 partners with QIAGEN to develop companion diagnostic for novel Parkinson's disease drug

Neuron23 partners with QIAGEN to develop companion diagnostic for novel Parkinson's disease drug

QIAGEN and Denovo Biopharma partner to develop CDx

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless